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Abstract
Background: It has been demonstrated that statins can increase intestinal sterol absorption. Augments in
phytosterolemia seems related to cardiovascular disease.
Objective: We examined the role of soluble fiber intake in endogenous cholesterol synthesis and in sterol
absorption among subjects under highly effective lipid-lowering therapy.
Design: In an open label, randomized, parallel-design study with blinded endpoints, subjects with primary
hypercholesterolemia (n = 116) were assigned to receive during 12 weeks, a daily dose of 25 g of fiber
(corresponding to 6 g of soluble fibers) plus rosuvastatin 40 mg (n = 28), rosuvastatin 40 mg alone (n = 30),
sinvastatin 40 mg plus ezetimibe 10 mg plus 25 g of fiber (n = 28), or sinvastatin 40 mg plus ezetimibe 10 mg (n
= 30) alone.
Results: The four assigned therapies produced similar changes in total cholesterol, LDL-cholesterol, and
triglycerides (p < 0.001 vs. baseline) and did not change HDL-cholesterol. Fiber intake decreased plasma
campesterol (p < 0.001 vs. baseline), particularly among those patients receiving ezetimibe (p < 0.05 vs. other
groups), and b-sitosterol (p = 0.03 vs. baseline), with a trend for lower levels in the group receiving fiber plus
ezetimibe (p = 0.07). Treatment with rosuvastatin alone or combined with soluble fiber was associated with
decreased levels of desmosterol (p = 0.003 vs. other groups). Compared to non-fiber supplemented individuals,
those treated with fibers had weight loss (p = 0.04), reduced body mass index (p = 0.002) and blood glucose (p =
0.047).
Conclusion: Among subjects treated with highly effective lipid-lowering therapy, the intake of 25 g of fibers added
favorable effects, mainly by reducing phytosterolemia. Additional benefits include improvement in blood glucose
and anthropometric parameters.
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Introduction
Dietary fiber is widely prescribed [1], alone or associated
with lipid-lowering therapies, in order to reduce choles-
terol levels [2]. The exact mechanism by which soluble
fibers lower serum LDL-cholesterol levels is not comple-
tely understood. However, there are evidences suggest-
ing that soluble fibers may interfere with lipid and/or
bile acid metabolism [3].
Atherosclerosis has been recognized as a complex dis-
ease related in part to lipid disorders. Beyond choles-
terol content of lipoproteins, a moderate increase in
phytosterolemia seems related to cardiovascular disease
[4,5].
Based on clinical trials, high doses of statins have been
recommended to achieve lower levels of LDL-cholesterol
[6-8]. Nevertheless, the use of high doses of statins is
not always well tolerated or effective and the concomi-
tant use of ezetimibe has been proposed. Due to the
blockade of the endogenous cholesterol synthesis [9],
statins appear related to increased intestinal absorption
of sterols, both cholesterol and plant sterols [10,11].
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reducing LDL-cholesterol and is able to prevent the
increase in intestinal sterols absorption [12,13]. On the
other hand, the inhibition of cholesterol absorption
increases the endogenous cholesterol synthesis [14-16].
The Framingham Offspring Study showed that choles-
terol synthesis markers were associated with reduction
in cardiovascular disease risk and, in contrast, absorp-
tion markers were associated with an almost two-fold
increased risk [17].
Although changes in lifestyle, including a prudent diet
[1] have been widely recommended for primary or sec-
ondary prevention of cardiovascular disease, the useful-
ness of a soluble fiber-enriched diet, in patients under
highly effective lipid-lowering therapy is less reported,
not only for the achievement of lipid goals, but particu-
larly to the balance between phytosterolemia and choles-
terol synthesis.
Therefore, we hypothesized that soluble fiber intake
can reduce plant sterols absorption among subjects
receiving highly effective lipid-lowering therapy. The
role of fiber intake was tested in two different lipid-low-
ering strategies, using high-dose statin or the combina-
tion of a statin plus a cholesterol absorption inhibitor.
These drugs and dosages were chosen to attain similar
changes in lipid profile through distinct mechanisms.
Subjects and methods
Design and study population
We performed a prospective, randomized, open label
study, with parallel arms and blinded endpoints. Patients
were recruited from the outpatient unit of dyslipidemias
of our university. The trial protocol was conducted in
accordance with the ethical standards of the institution
on human experimentation and approval was obtained
from the local ethics committee. Informed consent was
obtained from all participants prior inclusion. Eligible
patients were men and women, 30 to 75 years of age, in
primary or secondary prevention of coronary heart dis-
ease, who had an indication for lipid-lowering therapy
in accordance with the National Cholesterol Education
Program/Adult Treatment Panel (NCEP/ATP III) guide-
lines [1]. A total of 116 subjects completed the study
protocol. Patients with liver, renal or gastrointestinal
disease, malignancies, uncontrolled metabolic disorder,
that might affect the tolerability or safety of the treat-
ments were excluded. Exclusion criteria during the
study were low adherence (less than 80%) to either the
lipid-lowering regimen or to the daily fiber intake. The
major characteristics of the study population are listed
in the Table 1. Risk factors and metabolic syndrome
were defined by the NCEP/ATP III guidelines [1].
The 24-hour dietary recall [18] was obtained at the
beginning and end of the study. Before treatment, all
patients received nutritional counseling based on the
Therapeutic Lifestyle Changes of the NCEP/ATP III [1].
Then, they were randomized to receive or not 44 g of
the passion fruit peel flour, to ensure a minimum daily
consumption of 6 g of soluble fiber and to achieve the
target of 25 g of fiber intake, divided into three daily
doses administered before meals. They were also rando-
mized to rosuvastatin 40 mg or the combination of sim-
vastatin 40 mg plus ezetimibe 10 mg, daily for 12 weeks.
The lipid-lowering agents and the fiber were given to
the patients every 30 days, with reinforcement of life-
style changes and to evaluate the adherence to the study
protocol.
Study drugs and fiber
Rosuvastatin (Crestor
®, IPR Pharmaceuticals, Porto
Rico), Simvastatin/Ezetimibe (Zetsim
®,S c h e r i n g - P l o u g h
Products, Las Piedras, Porto Rico) were gifts from Astra-
Zeneca and Merck Co, respectively. The passion fruit
peel flour was purchased from Tango alimentos (Lon-
drina, PR, Brazil). The composition of passion fruit peel
flour was analyzed by Centro de Ciências e Qualidade
de Alimentos (Instituto de Tecnologia de Alimentos,
Campinas, SP, Brazil), which revealed that 44 g of flour
corresponded to 45 kcal of total energy, being 25 g of
total fiber, 6 g of soluble fiber, 5 mg of campesterol, and
35 mg of b-sitosterol.
Blood sample collection and assays
Lipids and biochemistry
Biochemical analyses were performed in samples
obtained after a 12-hour fasting period at baseline and
after 12 weeks of treatment in a central laboratory of
our university using automated techniques (Advia 2400,
Siemens Healthcare Diagnostics, Tokyo, Japan). Serum
cholesterol, HDL-cholesterol, and triglycerides were
determined by automated methods (Advia 2400, Sie-
mens Healthcare Diagnostics, Tokyo, Japan). LDL-cho-
lesterol was calculated using the Friedewald formula
[19]. Glycated hemoglobin was assayed by high-perfor-
mance liquid chromatopraphy (Tosho G2, Tosho Inc.,
Tokyo, Japan), apolipoprotein A1, apolipoprotein B, and
highly-sensitive C-reactive protein were determined by
nephelometry (Array 360 CE/AL, Beckmann Coulter,
Inc. Brea, CA).
Phytosterols and desmosterol
For the quantification of beta-sitosterol and campesterol
(markers of sterols absorption), as well as for desmosterol
(precursor of the endogenous cholesterol synthesis) we
used ultra performance liquid chromatography (UPLC)
and mass spectrometry (MS). Briefly, these sterols were
quantitated in plasma samples by a method developed
and run by Synchrophar, Campinas, SP, Brazil. The ster-
ols were detected as its free forms, i.e., non-esterified,
Ramos et al. Nutrition Journal 2011, 10:80
http://www.nutritionj.com/content/10/1/80
Page 2 of 8monitoring the ions with m/z, 367.30 for desmosterol,
397.25 for b-sitosterol and 383.60 for campesterol. The
levels of compounds were determined by comparison of
peak response against a calibration curve from 0.5 μg/mL
to 10.0 μg/mL. Samples presenting higher levels than
10.0 μg/mL were diluted to compare with calibration
levels. Results were transformed to mg/dL.
Statistical analyses
Results are expressed as mean (SEM) or percentages
unless otherwise specified. Continuous variables were
tested for distribution of normality by Kolmogorov-
Smirnov test. Comparisons between groups at baseline
were made by ANOVA or Pearson’s Chi square test. For
comparisons between timepoints and groups we used
General Linear Model (GLM) - repeated measures or
Kruskal-Wallis test, when data were presented as per-
centages. To compare non-fiber supplemented and
fiber-supplemented groups, the 2-sided Student’si n d e -
pendent or paired t-test or Mann-Whitney test were
used. When appropriate, continuous variables were log
transformed. Statistical significance was set at a p-value
< 0.05. All analyses were made using the SPSS 17.0 for
windows (SPSS Inc, Chicago, IL).
Results
Dietary intake, weight and body mass index
The analyses of the dietary recall have shown that the
consumption of cholesterol and dietary fiber did not dif-
fer between groups; monounsaturated, polyunsaturated,
or trans-fatty acids were also similar. Energy intake was
reduced at the 12 weeks (p = 0.001 vs. baseline, GLM-
repeated measures), with energy from carbohydrates,
fatty acids, and proteins being comparable among
groups. The estimated daily fiber intakes, obtained from
dietary recall were not different along the study, when
fiber supplementation with passion fruit peel flour was
not counted (Table 2).
Regarding the soluble fiber status, those with the addi-
tion of fiber presented weight (p = 0.04, Student’s t-test)
and BMI reduction (p = 0.002, Student’s t-test) on week
12 (Figure 1A-B).
Laboratory results
Lipids and apolipoproteins
In Table 3 we present our main laboratory findings.
Twelve-week treatment with lipid-lowering agents with or
without fiber supplementation was associated with effec-
tive reduction of total cholesterol (p < 0.0001 vs. baseline,
GLM-repeated measures), LDL-cholesterol (p < 0.001 vs.
baseline, GLM-repeated measures) and triglycerides (p <
0.001 vs. baseline, GLM-repeated measures), without
changes in HDL-cholesterol levels. Apolipoprotein B
serum levels were lower after a 12-week treatment period
(p < 0.001 vs. baseline, GLM-repeated measures), whereas
we observed higher levels of Apolipoprotein A1 (p = 0.035
vs. baseline, GLM-repeated measures), without differences
between treatments. Differences on lipids and apolipopro-
teins according to fiber intake status were not significant
(data not shown).
Desmosterol and phytosterols
Desmosterol plasma levels presented interaction
between groups. Subjects receiving rosuvastatin have
shown decreased levels of desmosterol in comparison
with the subjects treated with simvastatin plus ezetimibe
(p = 0.003 vs. other groups)
Sterol intestine absorption markers, campesterol and
b-sitosterol, are presented in Table 3. There was a
decrease in campesterol plasma levels at the end of treat-
ment (p < 0.001 vs. baseline, GLM-repeated measures),
with lower levels observed in subjects receiving fibers and
treated with simvastatin plus ezetimibe (p = 0.005
between groups, GLM-repeated measures). Campesterol
levels were lower for those subjects taking soluble fibers
on week 12 (p = 0.025 vs. non-fiber supplemented, Stu-
dent’s independent t-test) as shown in Figure 1C. There
was a decrease in plasma levels of b-sitosterol (p = 0.03
vs. baseline) with a trend for lower levels in the group
receiving fibers plus ezetimibe (p = 0.07). Fiber intake
status did not affect b-sitosterol plasma levels.
Glucose, glycated hemoglobin and C-reactive protein
Blood glucose and glycated hemoglobin (HbA1c) did not
change along the study between groups (Table 3). How-
ever, there were differences in glucose percent change in
subjects supplemented with fibers when compared with
Table 1 Baseline characteristics of the study population by group
RSV+Fib RSV SIM/EZE+Fib SIM+EZE P-value
N = 28 N = 30 N = 28 n = 30
Age, years
1 57 (1) 60 (2) 62 (1) 58 (1) 0.21
Female, n (%)
2 21 (75) 20 (67) 19 (68) 22 (73) 0.87
Hypertension, n (%)
2 22 (79) 24 (80) 18 (64) 26 (87) 0.22
Diabetes, n (%)
2 5 (18) 7 (23) 6 (21) 9 (30) 0.73
Smoking, n (%)
2 2 (7) 3 (10) 1 (4) 2 (7) 0.82
Metabolic Syndrome, n (%)
2 17 (61) 18 (60) 13 (46) 14 (47) 0.53
Differences between groups were analyzed by ANOVA
1, or Pearson’s chi-square test
2. RSV = rosuvastatin; Fib = fiber; SIM = simvastatin; EZE = ezetimibe.
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0.6 (4.3) %, p = 0.038, Mann-Whitney test]. Glucose
levels were lower in subjects supplemented with fibers
on week 12 (p = 0.035 vs. non-supplemented, Student’s
independent t-test); data shown in Figure 1D.
Highly-sensitive C-reactive protein serum levels were
elevated at baseline and decreased similarly between
treatment groups (p < 0.001 vs. baseline, GLM-repeated
measures) (Table 3). We did not observe differences in
highly-sensitive C-reactive protein according to fiber
intake status (data not shown).
Discussion
This study examined the role of fiber supplementation
in patients under effective therapy with lipid-lowering
drugs. It has been reported that consumption of soluble
fibers promotes a moderate effect in lowering choles-
terol in hypercholesterolemic patients [20,21]. However,
the literature is scarce in relation to the benefit of fibers
added to therapy in patients taking effective lipid-lower-
ing agents. Our study has shown that no further reduc-
tion was achieved in total cholesterol, LDL-cholesterol,
and triglycerides when fibers were added to an effective
therapy. However, fibers seemed to act synergistically
with ezetimibe, reducing phytosterolemia, at the recom-
mended dose for total (25 g) and soluble fibers (6 g)
intake [1].
However, the addition of fibers to the diet, even in
patients receiving highly effective therapy can bring
important benefits [22,23]. It has been reported that use
of statins alone may increase the absorption of sterols
by the intestine, causing mild to moderate increase in
plasma phytosterols [14]. This increase appears to be
related to statin dose [15,16,24]. Although phytosterole-
mia, as recessive genetic disease related to deficiency of
ABCG5/G8 carriers, is very rare, mild to moderate
increases in phytosterolemia may be associated with
increased cardiovascular risk [4,25], although this topic
is still controversial [26]. The greatest contribution of
our study was to show that the use of fibers in patients
on highly effective lipid-lowering therapy, in order to
reduce LDL-C > 50% and attain guideline goals, can
prevent the increase in plant sterols plasma levels.
Furthermore, among patients receiving therapy with
simvastatin and ezetimibe, the use of fibers produced
significant decrease in phytosterolemia. These findings
seem of importance, because they support evidence for
supplementation of fibers being a safe strategy when
added to the most effective lipid-lowering strategies,
reducing the absorption of phytosterols. These aspects
seem yet more relevant for subjects bearing common
polymorphisms of the NPC1L1 or ABCG5/G8 genes.
Genetic variation in these genes were reported and can
increase the absorption of sterols or decrease sterol
extrusion to the intestinal lumen, which are associated
with increased levels of phytosterolemia [27].
Other benefits of fiber supplementation observed in
our patients were weight loss and the achievement of
lower body mass index. The reduction in total energy
intake may have contributed to these results, however,
differences between groups were only observed in
patients receiving fiber supplementation. Our findings
are in agreement with previous studies showing inverse
relationship between fiber intake and weight loss [28,29].
Another interesting findingo ft h es t u d yw a st h em i l d
reduction in blood glucose in subjects receiving fiber
Table 2 Characteristics of the diet consumed at baseline
and 12 weeks, by group
RSV+Fib RSV SIM/EZE
+Fib
SIM
+EZE
P-
value
N = 28 N = 30 N = 28 n = 30
MUFA%
1
Baseline 13.8 (0.7) 12.8 (0.7) 13.4 (1.0) 11.8 (0.7) 0.374
12 weeks 12.9 (0.6) 13.6 (0.8) 13.4 (0.5) 11.5 (0.6) 0.094
PUFA%
1
Baseline 9.1 (0.6) 11.9 (1.0) 10.3 (0.8) 10.3 (1.0) 0.329
12 weeks 8.3 (0.8) 10.7 (1.1) 9.6 (0.6) 8.2 (0.7) 0.098
SAFA%
1
Baseline 9.7 (0.6) 9.5 (0.6) 9.5 (0.5) 9.1 (0.6) 0.833
12 weeks 9.3 (0.5) 9.4 (0.5) 9.5 (0.7) 8.9 (0.7) 0.717
Trans FA%
1
Baseline 0.3 (0.1) 0.4 (0.1) 0.3 (0.1) 0.3 (0.1) 0.608
12 weeks 0.3 (0.1) 0.4 (0.1) 0.4 (0.2) 0.4 (0.1) 0.237
Energy Kcal/day
2
Baseline 1762
(116)
1766
(100)
1828 (156) 1741
(136)
0.001
a
12 weeks 1653
(116)
1520
(85)
1585 (129) 1599
(102)
0.990
b
Lipids%
1
Baseline 36.1 (1.4) 37.3 (1.9) 36.3 (1.7) 34.3 (1.8) 0.941
12 weeks 33.9 (1.4) 36.9 (1.8) 35.7 (1.2) 31.4 (1.6) 0.041
Carbohydrates%
1
Baseline 46.4 (1.9) 46.9 (2.1) 46.7 (2.3) 49.2 (2.1) 0.869
12 weeks 46.3 (1.5) 46.5 (1.6) 46.7 (1.7) 52.1 (1.8) 0.034
Proteins%
1
Baseline 18 (1.3) 16.5 (1.0) 17.7 (1.3) 17.3 (0.9) 0.79
12 weeks 20 (1.0) 17.6 (0.9) 18.5 (1.2) 17.8 (0.8) 0.268
Cholesterol mg/
day
2
Baseline 214 (29) 200 (21) 197 (33) 210 (29) 0.203
a
12 weeks 222 (29) 157 (12) 201 (34) 171 (22) 0.683
b
Fibers g/day
2
Baseline 20 (3) 17 (1) 22 (3) 16 (2) 0.853
a
12 weeks 20 (2) 16 (1) 18 (2) 19 (2) 0.666
a
Differences analyzed by Kruskal-Wallis test
1 or General Linear Model-repeated
measures followed by Tukey’s test
2, with p-values for comparisons
abetween
visits and
bbetween groups.
MUFA = monounsaturated fatty acids; PUFA = polyunsaturated fatty acids;
SAFA = saturated fatty acids; RSV = rosuvastatin 40 mg; Fib = fiber; SIM =
simvastatin 40 mg; EZE = ezetimibe 10 mg; FA = fatty acids.
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reduction in fasting glucose, postprandial and glycated
hemoglobin levels associated with soluble fiber intake
[30-33]. Recently, two meta-analyses have shown a slight
increase in the rates of new-onset diabetes mellitus in
patients treated with statins [34,35]. Another contribu-
tion of fiber intake is the potential benefit for reduction
in new cases of diabetes, attributed to statin therapy.
Study strenghts and limitations
According to a recent meta-analysis of statin trials [36],
lipid-lowering therapy that promotes greater reductions
in LDL-cholesterol produces definite further reductions
in the incidence of cardiovascular events. Therefore, our
study tested the benefit of fiber intake in this scenario.
It is possible that the lipid effects of soluble fiber have
been masked by the highly effective treatment used in
Figure 1 Box plots of (A) Weight, (B) BMI, (C) Campesterol and (D) Glucose at baseline (white bars) and 12 weeks (dashed bars). Fiber-
supplemented subjects presented mild reduction in body weight (*p = 0.04 vs. non-fiber supplemented, Student’s paired t-test), body mass
index (*p = 0.002 vs. non-fiber supplemented, Student’s paired t-test), reduction in campesterol levels (*p = 0.033 vs. non-fiber supplemented,
Student’s paired t-test; †p = 0.025 vs. non-fiber supplemented, Student’s independent t-test) and in blood glucose (†p = 0.035 vs. non-fiber
supplemented, Student’s independent t-test). BMI = body mass index.
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RSV+Fib RSV SIM/EZE+Fib SIM+EZE P-value
1 P-value
2
N = 28 N = 30 N = 28 n = 30
Weight kg
Baseline 74 (3) 72 (2) 73 (3) 70 (2) 0.001 0.803
12 weeks 73 (3) 72 (3) 72 (3) 70 (2)
BMI kg/m
2
Baseline 28 (1) 30 (1) 30 (1) 28 (1) 0.005 0.246
12 weeks 27 (1) 30 (1) 29 (1) 28 (1)
Glucose mg/dL
Baseline 97 (2) 104 (4) 103 (5) 108 (7) 0.754 0.257
12 weeks 95 (2) 104 (4) 100 (4) 109 (6)
HbA1c %
Baseline 5.7 (0.1) 6.3 (0.2) 6.0 (0.2) 6.2 (0.2) 0.02 0.215
12 weeks 5.8 (0.1) 6.2 (0.2) 6.1 (0.2) 6.3 (0.2)
hsCRP mg/L
Baseline 4.2 (1.1) 3.7 (0.5) 3.3 (0.4) 4.5 (1.3) <0.001 0.976
12 weeks 2.4 (0.5) 2.5 (0.4) 2.3 (0.4) 2.3 (0.4)
Cholesterol mg/dL
Baseline 256 (10) 244 (8) 247 (8) 241 (9) <0.0001 0.639
12 weeks 149 (6) 140 (5) 155 (9) 147 (8)
LDL-C mg/dL
Baseline 167 (8) 154 (7) 162 (6) 158 (8) <0.001 0.436
12 weeks 70 (5) 64 (4) 80 (8) 72 (4)
HDL-C mg/dL
Baseline 57 (3) 52 (2) 52 (2) 54 (2) 0.392 0.351
12 weeks 57 (3) 50 (3) 53 (3) 52 (2)
Triglycerides mg/dL
Baseline 160 (13) 187 (16) 158 (14) 144 (10) <0.001 0.291
12 weeks 110 (9) 123 (8) 110 (7) 108 (9)
Apoliprotein A1 mg/dL
Baseline 153 (6) 145 (6) 141 (4) 147 (3) 0.035 0.482
12 weeks 155 (6) 149 (6) 145 (5) 152 (4)
Apoliprotein B mg/dL
Baseline 133 (6) 133 (5) 133 (5) 134 (6) <0.001 0.775
12 weeks 68 (3) 67 (3) 73 (5) 70 (4)
Campesterol mg/dL
Baseline 1.2 (0.2) 1.1 (0.1) 0.9 (0.1) 1.3 (0.2) <0.001 0.005
12 weeks 0.9 (0.1) 1.0 (0.1) 0.5 (0.1) 0.8 (0.1)
b-sitosterol mg/dL
Baseline 0.7 (0.1) 0.8 (0.1) 0.6 (0.1) 0.9 (0.1) 0.03 0.072
12 weeks 0.6 (0.6) 0.7 (0.1) 0.5 (0.1) 0.6 (0.1)
Desmosterol mg/dL
Baseline 0.7 (0.1) 1.9 (1.6) 0.9 (0.3) 0.5 (0.1) 0.005 0.373
12 weeks 0.6 (0.1) 0.9 (0.5) 1.0 (0.3) 1.6 (0.5)
Differences analyzed by General Linear Model-repeated measures, followed by Tukey’s test. HbA1c = glycated hemoglobin; hs-CRP = highly-sensitive C-reactive
protein; RSV = rosuvastatin 40 mg; Fib = fiber; SIM = simvastatin 40 mg; EZE = ezetimibe 10 mg.
1Differences between baseline and 12 week;
2Differences
between groups.
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parameters could be more pronounced in subjects with
obesity and/or diabetes, and when fiber is consumed at
longer periods.
Conclusions
Soluble fiber intake in patients receiving effective strate-
gies with lipid-lowering drugs seems important for the
achievement of lower phytosterolemia (synergistic action
with ezetimibe), and is associated with weight loss, and
lower levels of plasma glucose.
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